申请人:William H. Rorer, Inc.
公开号:US04203983A1
公开(公告)日:1980-05-20
1,4-disubstituted-1,2-dihydro-1,3,5-triazin-2-ones and their pharmaceutically acceptable salts are used in the control of abdominal spasticity especially the treatment of spasmodic conditions of the gastrointestinal tract by administering an effective amount of the triazinone in suitable pharmaceutical dosage forms including oral or parenteral dosage forms compounded with pharmaceutically acceptable carrier materials to patients having spasmodic syndromes.
1,4-二取代-1,2-二氢-1,3,5-三嗪-2-酮及其药学上可接受的盐被用于控制腹部痉挛,特别是通过向具有痉挛综合症的患者施用适量的三嗪酮,包括口服或静脉注射剂型,并与药学上可接受的载体材料混合制成适宜的药物剂量形式,治疗胃肠道痉挛症状。